Featured
Moleculin Biotech, Inc. is a public clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of highly resistant tumors and viruses. The company’s lead program, Annamycin is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity. With a need to add…
Read More
Pyxis Oncology are an exciting Boston based biotech working on antibody drug conjugates and monoclonal antibodies to treat a range of cancer indications. They had raised around $200m from top tier investors including RA Capital, Pfizer Ventures, Longwood Fund, Ipsen Ventures, Perceptive Advisors, BVF Partners and more. Approaching their IPO date with no CMO on…
Read More